Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension

Editorial Material Rheumatology

Sex Effect in Psoriatic Arthritis

Dafna D. Gladman

JOURNAL OF RHEUMATOLOGY (2023)

Article Rheumatology

Depression and Anxiety Reduce the Probability of Achieving a State of Sustained Minimal Disease Activity in Patients With Psoriatic Arthritis

Antonio Wong et al.

Summary: This study found that symptoms of anxiety/depression reduce the probability of achieving sustained MDA in PsA patients. Comprehensive management of PsA should include measures to address these comorbidities.

ARTHRITIS CARE & RESEARCH (2022)

Add to Collection

Article Rheumatology

Potential Impact of Sex and BMI on Response to Therapy in Psoriatic Arthritis: Post Hoc Analysis of Results From the SEAM-PsA Trial

Philip J. Mease et al.

Summary: This post hoc analysis examined the potential impact of sex and BMI on response in the SEAM-PsA trial, which compared different treatment options for PsA patients. The results showed that sex and BMI may affect treatment outcomes.

JOURNAL OF RHEUMATOLOGY (2022)

Add to Collection

Article Rheumatology

Responses to Ixekizumab in Male and Female Patients with Psoriatic Arthritis: Results from Two Randomized, Phase 3 Clinical Trials

Lihi Eder et al.

Summary: This study found that female PsA patients had lower response rates to ixekizumab treatment compared to male patients, with significant differences observed at multiple time points.

RHEUMATOLOGY AND THERAPY (2022)

Add to Collection

Article Rheumatology

Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies

Christopher T. Ritchlin et al.

Summary: The study evaluated the efficacy of guselkumab in PsA patients and found that both Q4W and Q8W treatments resulted in robust and sustained improvements in signs and symptoms across subgroups defined by diverse baseline characteristics.

RMD OPEN (2022)

Add to Collection

Article Rheumatology

Real-World Treatment Persistence with Biologic Disease-Modifying Antirheumatic Drugs Among German Patients with Psoriatic Arthritis-A Retrospective Database Study

Philipp Sewerin et al.

Summary: This study investigated drug survival for bDMARDs in German PsA patients, finding an overall persistence rate of 57.5% with variations depending on the specific bDMARD used. Male patients had a significantly lower risk of treatment discontinuation.

RHEUMATOLOGY AND THERAPY (2021)

Add to Collection

Meeting Abstract Rheumatology

SEX DIFFERENCES IN THE EFFICACY AND SAFETY OF TOFACITINIB IN RHEUMATOID ARTHRITIS PATIENTS: A POST HOC ANALYSIS OF PHASE 3 AND LONG-TERM EXTENSION TRIALS

H. N. Jones et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Rheumatology

Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study

Roberta Ramonda et al.

Summary: In a multicentric Italian cohort of patients with Psoriatic Arthritis (PsA), secukinumab showed long-term effectiveness and safety, with notable drug retention rate in a real-life clinical setting.

RMD OPEN (2021)

Add to Collection

Article Rheumatology

Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance

Peter Nash et al.

Summary: The study evaluated the efficacy and safety of tofacitinib 5 mg twice daily monotherapy after methotrexate withdrawal in patients with psoriatic arthritis. The findings suggest that some patients with stable psoriatic arthritis on tofacitinib may be able to discontinue methotrexate without significant changes in disease activity and safety.

LANCET RHEUMATOLOGY (2021)

Add to Collection

Article Dermatology

Effect of Sex in Systemic Psoriasis Therapy: Differences in Prescription, Effectiveness and Safety in the BIOBADADERM Prospective Cohort

Carlos Pelayo Hernandez-Fernandez et al.

Summary: This study found that women with psoriasis are more likely to be prescribed biologics than men, but there were no significant differences between sexes in terms of treatment effectiveness and risk of adverse events. Limitations of the study include residual confounding and the use of drug survival as a proxy for effectiveness.

ACTA DERMATO-VENEREOLOGICA (2021)

Add to Collection

Article Rheumatology